Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

PARP inhibitors have changed the management of advanced high-grade epithelial ovarian cancer (EOC), especially homologous recombinant (HR)-deficient advanced high-grade EOC. However, the effect of PARP inhibitors on HR-proficient (HRP) EOC is limited. Thus, new therapeutic strategy for HRP EOC is de...

Descripción completa

Detalles Bibliográficos

Autores principales:	Yasushi Iida, Nozomu Yanaihara, Yuki Yoshino, Misato Saito, Ryosuke Saito, Junya Tabata, Ayako Kawabata, Masataka Takenaka, Natsuko Chiba, Aikou Okamoto
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2024-02-01
Colección:	Frontiers in Oncology
Materias:	ovarian cancer olaparib bevacizumab homologous recombinant proficient CRY1
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1302850/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!